Status:
UNKNOWN
Effectiveness Evaluation of the Sinopharm Vaccine in the Dondo District in Mozambique
Lead Sponsor:
International Vaccine Institute
Collaborating Sponsors:
The Coalition for Epidemic Preparedness Innovations (CEPI)
Instituto Nacional de Saúde, Mozambique
Conditions:
Sars-CoV-2 Infection
Eligibility:
All Genders
18+ years
Brief Summary
Three complementary activities will be implemented:1) Baseline and repeat census of the catchment population; described in a separate protocol (IVI-ECOVA-03-WS1); 2) Enhanced surveillance for COVID-19...
Eligibility Criteria
Inclusion
- They resided in the study area at the time of mass immunization with the Sinopharm vaccine; and
- They are at least 18 years of age during first round of mass vaccination.
- Their onset of symptoms was \<10 days prior to testing.
- For each selected PCR test-positive case, we will select up to 3 test-negative controls from generally eligible subjects, matched to each case by age on the date of testing, sex, and calendar date of testing + 3 days.
Exclusion
- We will exclude subjects for selection as controls if they have had a positive test result within the following 21 days
- Any Participant not matching the inclusion criteria mentioned above.
Key Trial Info
Start Date :
February 24 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 30 2024
Estimated Enrollment :
3000 Patients enrolled
Trial Details
Trial ID
NCT05362682
Start Date
February 24 2022
End Date
August 30 2024
Last Update
April 19 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dondo Health Facility
Dondo, Mozambique, 2104